Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021

August 31, 2021 Auto Bot Boehringer Ingelheim, Clinical Trials, Eli Lilly, Empagliflozin, Jardiance, P-III 0

Shots:

  • The P-III EMPEROR-Preserved trial evaluates the safety & efficacy of empagliflozin (10mg, qd) vs PBO in 5988 patients with chronic HFpEF
  • The results demonstrated a 21% reduction in risk for composite 1EPs of CV death or hospitalization for HF. The 2EPs showed a 27% reduction in risk of first & recurrent hospitalizations for HF & slowed kidney function decline, safety data were consistent with previous findings with well-established safety profile of empagliflozin, results are published in the NEJM
  • The companies plan for regulatory submissions globally in 2021. If approved, empagliflozin will be the 1st therapy across the HF spectrum

Click here to­ read full press release/ article | Ref: Businesswire | Image: Longevity Technology

The post Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021 first appeared on PharmaShots.